Leerink Partnrs Weighs in on MoonLake Immunotherapeutics’ FY2028 Earnings (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTXFree Report) – Analysts at Leerink Partnrs issued their FY2028 earnings per share estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of $2.51 for the year. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($0.85) per share.

MoonLake Immunotherapeutics (NASDAQ:MLTXGet Free Report) last issued its quarterly earnings data on Tuesday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05.

Other equities research analysts also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and issued a $76.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, October 16th. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Monday, November 27th. Stifel Nicolaus lifted their price target on shares of MoonLake Immunotherapeutics from $66.00 to $69.00 and gave the company a “buy” rating in a research report on Monday, December 18th. Wedbush reissued an “outperform” rating and set a $92.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Friday, December 1st. Finally, Guggenheim lifted their target price on shares of MoonLake Immunotherapeutics from $70.00 to $77.00 and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.20.

View Our Latest Stock Report on MLTX

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX stock opened at $61.25 on Wednesday. MoonLake Immunotherapeutics has a 1 year low of $13.63 and a 1 year high of $63.78. The firm has a market cap of $3.83 billion, a price-to-earnings ratio of -64.47 and a beta of 1.30. The stock’s 50-day moving average is $57.14 and its two-hundred day moving average is $54.19.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Silverarc Capital Management LLC grew its position in MoonLake Immunotherapeutics by 89.1% in the 2nd quarter. Silverarc Capital Management LLC now owns 200,000 shares of the company’s stock worth $10,200,000 after purchasing an additional 94,250 shares during the last quarter. Cormorant Asset Management LP lifted its stake in shares of MoonLake Immunotherapeutics by 18.1% in the 2nd quarter. Cormorant Asset Management LP now owns 8,142,100 shares of the company’s stock worth $415,247,000 after acquiring an additional 1,249,999 shares during the period. TD Asset Management Inc lifted its stake in shares of MoonLake Immunotherapeutics by 101.1% in the 3rd quarter. TD Asset Management Inc now owns 200,390 shares of the company’s stock worth $11,422,000 after acquiring an additional 100,750 shares during the period. ArrowMark Colorado Holdings LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the 2nd quarter worth approximately $510,000. Finally, Victory Capital Management Inc. lifted its stake in shares of MoonLake Immunotherapeutics by 773.4% in the 3rd quarter. Victory Capital Management Inc. now owns 182,977 shares of the company’s stock worth $10,430,000 after acquiring an additional 162,027 shares during the period.

Insider Activity at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, CFO Matthias Bodenstedt sold 94,736 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $59.22, for a total value of $5,610,265.92. Following the completion of the transaction, the chief financial officer now owns 526,167 shares in the company, valued at approximately $31,159,609.74. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 15.27% of the company’s stock.

About MoonLake Immunotherapeutics

(Get Free Report)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis.

See Also

Earnings History and Estimates for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.